Ascentage Pharma Group International (NASDAQ:AAPG) Hits New 12-Month Low – Here’s What Happened

Ascentage Pharma Group International – Unsponsored ADR (NASDAQ:AAPG) shares hit a new 52-week low during trading on Wednesday . The stock traded as low as $15.01 and last traded at $18.9690, with a volume of 501 shares changing hands. The stock had previously closed at $18.98.

Wall Street Analyst Weigh In

A number of research firms have recently weighed in on AAPG. Deutsche Bank Aktiengesellschaft began coverage on Ascentage Pharma Group International in a research report on Friday, April 24th. They issued a “buy” rating and a $40.00 price objective for the company. BTIG Research reiterated a “buy” rating and issued a $48.00 price target on shares of Ascentage Pharma Group International in a research note on Monday, June 15th. Raymond James Financial reissued a “buy” rating on shares of Ascentage Pharma Group International in a report on Wednesday, June 10th. Finally, B. Riley Financial started coverage on Ascentage Pharma Group International in a research note on Wednesday, June 10th. They set a “buy” rating and a $45.00 price target on the stock. Two analysts have rated the stock with a Strong Buy rating and eight have issued a Buy rating to the stock. Based on data from MarketBeat, the company has an average rating of “Buy” and an average target price of $46.43.

Ascentage Pharma Group International Stock Performance

The company has a current ratio of 1.79, a quick ratio of 1.77 and a debt-to-equity ratio of 0.57. The business’s fifty day moving average price is $18.09 and its two-hundred day moving average price is $21.58.

Institutional Trading of Ascentage Pharma Group International

Several large investors have recently added to or reduced their stakes in the company. UBS Group AG increased its holdings in shares of Ascentage Pharma Group International by 149.4% in the third quarter. UBS Group AG now owns 18,345 shares of the company’s stock valued at $716,000 after purchasing an additional 10,988 shares during the period. Hsbc Holdings PLC acquired a new stake in shares of Ascentage Pharma Group International during the second quarter worth about $391,000. Finally, Citadel Advisors LLC acquired a new stake in shares of Ascentage Pharma Group International during the third quarter worth about $383,000.

About Ascentage Pharma Group International

Ascentage Pharma Group International is a clinical‐stage biopharmaceutical company focused on developing small‐molecule therapeutics that modulate programmed cell death pathways, including the Bcl‐2 family and the MDM2–p53 axis. Its pipeline features orally bioavailable inhibitors such as APG-2575, a selective Bcl-2 inhibitor, and APG-115, a potent MDM2 antagonist, both aimed at reactivating apoptosis in cancer cells across hematologic malignancies and solid tumors.

Founded in 2008 by biotechnology entrepreneur Dr.